MX2018005259A - Inhibidores de gelatinasa y uso de los mismos. - Google Patents

Inhibidores de gelatinasa y uso de los mismos.

Info

Publication number
MX2018005259A
MX2018005259A MX2018005259A MX2018005259A MX2018005259A MX 2018005259 A MX2018005259 A MX 2018005259A MX 2018005259 A MX2018005259 A MX 2018005259A MX 2018005259 A MX2018005259 A MX 2018005259A MX 2018005259 A MX2018005259 A MX 2018005259A
Authority
MX
Mexico
Prior art keywords
diseases
disease
gelatinase inhibitors
inflammatory
gelatinases
Prior art date
Application number
MX2018005259A
Other languages
English (en)
Inventor
Prades Cosano Roger
SECO MORAL Jesus
Teresa Tarrago Clua Maria
Original Assignee
Iproteos S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iproteos S L filed Critical Iproteos S L
Publication of MX2018005259A publication Critical patent/MX2018005259A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Nuevos inhibidores de gelatinasa, procedimientos para su preparación, composiciones farmacéuticas que los comprenden, y su uso en la terapia y/o profilaxis de afecciones en las que la inhibición de ñas gelatinasas es útil tal como epilepsia, esquizofrenia, enfermedad de Alzheimer, autismo (en particular, asociado al síndrome del cromosoma X frágil), retraso mental, trastornos del estado de ánimo tales como trastornos bipolares, depresión, vasculopatias tales como apoplejía isquémica y aterosclerosis, enfermedades inflamatorias tales como esclerosis múltiple, artritis reumatoide y enfermedad inflamatoria del intestino, toxicomanía, dolor neurópatico, enfermedades pulmonares tales como asma y enfermedad pulmonar obstructiva crónica, cáncer y septicemia. Adicción a las drogas, dolor neuropático, enfermedades pulmonares como asma y enfermedad pulmonar obstructiva crónica, cáncer y sepsis.
MX2018005259A 2015-11-16 2016-11-15 Inhibidores de gelatinasa y uso de los mismos. MX2018005259A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382567 2015-11-16
PCT/EP2016/077632 WO2017085034A1 (en) 2015-11-16 2016-11-15 Gelatinase inhibitors and use thereof

Publications (1)

Publication Number Publication Date
MX2018005259A true MX2018005259A (es) 2018-08-16

Family

ID=54754574

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005259A MX2018005259A (es) 2015-11-16 2016-11-15 Inhibidores de gelatinasa y uso de los mismos.

Country Status (16)

Country Link
US (1) US10414797B2 (es)
EP (1) EP3377515B1 (es)
JP (1) JP6795606B2 (es)
KR (1) KR102649684B1 (es)
CN (1) CN108290925B (es)
AU (1) AU2016356876B2 (es)
BR (1) BR112018009641A2 (es)
CA (1) CA3002892A1 (es)
EA (1) EA036732B1 (es)
ES (1) ES2766548T3 (es)
HK (1) HK1255029A1 (es)
IL (1) IL259286B (es)
MX (1) MX2018005259A (es)
NZ (1) NZ741898A (es)
WO (1) WO2017085034A1 (es)
ZA (1) ZA201803212B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107987126B (zh) * 2017-12-18 2018-10-02 哈尔滨工业大学 4位苯丙酰胺羟基化修饰的内吗啡肽类似物及其合成方法和应用
JPWO2022097540A1 (es) * 2020-11-05 2022-05-12

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2573006B2 (ja) 1987-12-17 1997-01-16 富士薬品工業株式会社 新規なヒドロキサム酸誘導体
WO1992022523A2 (en) * 1991-06-14 1992-12-23 Research Corporation Technologies, Inc. Peptide derivatives of collagenase inhibitor
WO1998015525A1 (fr) * 1996-10-07 1998-04-16 Sumitomo Pharmaceuticals Co., Ltd. Acides hydroxamiques
WO2009097893A1 (en) * 2008-02-04 2009-08-13 Proyecto De Biomedicina Cima, S.L. Methods for the treatment of cardiac disease associated to myocardial fibrosis using an inhibitor of pcp

Also Published As

Publication number Publication date
CN108290925A (zh) 2018-07-17
WO2017085034A1 (en) 2017-05-26
JP2018535258A (ja) 2018-11-29
IL259286A (en) 2018-07-31
AU2016356876B2 (en) 2020-10-01
CN108290925B (zh) 2021-12-24
AU2016356876A1 (en) 2018-05-10
ES2766548T3 (es) 2020-06-12
KR20180071388A (ko) 2018-06-27
BR112018009641A2 (pt) 2018-11-06
JP6795606B2 (ja) 2020-12-02
EA201891184A1 (ru) 2018-11-30
CA3002892A1 (en) 2017-05-26
US10414797B2 (en) 2019-09-17
IL259286B (en) 2021-10-31
EP3377515B1 (en) 2019-10-30
NZ741898A (en) 2024-02-23
ZA201803212B (en) 2020-08-26
EP3377515A1 (en) 2018-09-26
EA036732B1 (ru) 2020-12-14
KR102649684B1 (ko) 2024-03-21
HK1255029A1 (zh) 2019-08-02
US20180319839A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
MX2021015106A (es) Inhibidores de ferroportina novedosos.
PH12017501921A1 (en) Novel compounds
NZ741082A (en) C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
PH12018500828A1 (en) Jak kinase inhibitor compounds for treatment of respiratory disease
MX2018002631A (es) Inhibidores de molecula pequeña de dyrkia y usos de los mismos.
MX2014007254A (es) Composiciones farmaceuticas que comprenden glitazonas y activadores de nrf2.
BR112012026257A2 (pt) formas sólidas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico
MX2017011778A (es) Compuestos y composiciones de alfa-cinamida como inhibidores de histona desacetilasa 8 (hdac8).
MY183969A (en) Combination of regorafenib and acetylsalicylic acid for treating cancer
IN2014DN07885A (es)
GEP20186885B (en) Novel compounds
IN2014CN03290A (es)
BR112015018071A2 (pt) estra-1,3,5(10),16-tetraeno-3-carboxamidas
NZ741898A (en) Gelatinase inhibitors and use thereof
TN2016000107A1 (en) Substituted phenylalanine derivatives
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
SA520412289B1 (ar) مركبات مثبط الهدف الميكانيكي للراباميسين
PH12017500383B1 (en) Pyrazolothiazole compound and medicine comprising same
EA201790321A1 (ru) Эластомерные композиции, содержащие усниновую кислоту, и изделия, изготовленные из них или покрытые ими
WO2014108336A8 (en) Pyrazolyl-based carboxamides ii as crac channel inhibitors
WO2014108337A8 (en) Pyrazolyl-based carboxamides i as crac channel inhibitors
MX2018010334A (es) Cristal de compuesto que tiene actividad inhibidora de la cinasa de janus (jak).
MX2017003016A (es) Derivados de piridazinona como inhibidores de las fosfoinositido-3-cinasas.
CY1123075T1 (el) Μεθοδος αγωγης και συνθεσεις που περιλαμβανουν εναν διπλο αναστολεα κινασης ρι3κ δελτα-γαμα και ενα κορτικοστεροειδες
MX2020012065A (es) Compuestos de ciclopentano.

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: ACCURE THERAPEUTICS, S.L.